Open Orphan plc announced that hVIVO, a subsidiary of Open Orphan, has signed a £5 million respiratory syncytial virus ("RSV") human challenge study contract with a European biotechnology company ("European biotech") to test its intravenous antiviral candidate, using the hVIVO RSV Human Challenge Study Model. The study is expected to commence this year and will test and assess the efficacy of the client's antiviral candidate in a cohort of healthy young adult volunteers. This contract builds on Open Orphan's existing relationship with this European biotech, following previous early clinical work completed by the Venn Breda team, highlighting the Company's ability to maintain relationships with its clients over time and to cross sell services between brands.

The Company expects the revenues from the contract to be recognised across 2022 and 2023.